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EXPERT OPINION
Objective: To review the pharmacokinetics, efficacy, safety, and cost-effectiveness of long-
acting risperidone.
Methods: Studies published between January 2000 and October 2006 evaluating the
pharmacokinetics, efficacy, safety, and cost-effectiveness of long-acting risperidone were
reviewed, as identified from literature searches using Medline and EMBASE. Abstracts and
posters on long-acting risperidone presented at key psychiatry congresses and available in
the public domain during this time period were also reviewed.
Results: The unique pharmacokinetic profile of long-acting risperidone is derived from the
encapsulation of risperidone in a glycolide/lactide matrix in the form of microspheres such
that after a single intramuscular injection, significant plasma levels of the drug are achieved
after week 3. Steady state, after repeated administration at 2-week intervals, is achieved after
3 injection cycles. Short- and long-term studies have demonstrated that long-acting risperidone
(25, 37.5, or 50 mg) is both efficacious and well tolerated in a wide variety of patients with
schizophrenia and related psychoses. Most patients can be switched from other oral and long-
acting antipsychotic agents without compromising efficacy and safety. Long-acting risperidone
may also reduce overall healthcare costs by decreasing rates of relapse and hospitalization.
Conclusion: The assured delivery of an atypical antipsychotic medication with long-acting
risperidone has important implications for patient compliance, maintenance of stability,
consistency of treatment, and improving patient outcomes including the achievement of
remission.
Keywords: long-acting injectable risperidone, efficacy, safety, pharmacokinetics,
pharmacoeconomics, schizophrenia
Introduction
The long-acting injectable antipsychotics were developed in the 1960s as an additional
method of drug delivery aimed specifically at improving treatment compliance in
patients with schizophrenia, as well as simplifying the medication process. Long-
acting antipsychotics are convenient for the patients and their families, in that patients
no longer have the burden of remembering to take daily medication, and families no
longer have to regularly monitor and remind their family member about their
medication. Moreover, from the clinician’s point of view, a critical advantage of
long-acting antipsychotics is that if a patient does become non-compliant, the clinical
team will know immediately (because an injection has been missed) and will be able
to initiate efforts to deal effectively with the problem before symptoms reappear
(Valenstein et al 2001). Long-acting injectable antipsychotics are not associated with
“first-pass metabolism” and can be adjusted more reliably to the lowest effective
dose, thereby further reducing the risk of adverse effects (Ereshefsky et al 1984;
Ereshefsky and Mascarenas 2003). A less well recognized benefit of long-acting
therapy is the regular contact between patients and treatment teams, which provides
the opportunity for greater therapeutic alliance and psychosocial interventions.
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Consistent with this, data from a number of individual trials
and meta-analyses have shown that, compared with oral
antipsychotics, long-acting antipsychotics reduce relapse
frequency and rehospitalization rates (Davis et al 1994;
Gerlach 1994) and lower annual treatment costs (Glazer and
Ereshefsky 1996). However, despite the attractiveness of
this treatment option, the use of long-acting antipsychotics
has fallen in recent years particularly in North America,
likely as the result of the introduction and widespread use
of the oral atypical antipsychotics.
The development of the atypical antipsychotic agents
over the last decade was a major step forward in the
pharmacological management of schizophrenia, with
numerous studies demonstrating that atypical agents
improve negative symptoms (Lindenmayer et al 1994;
Marder and Meibach 1994; Boyer et al 1995; Beasley et al
1996) and cognitive function (Meyer-Lindenberg et al 1997;
Keefe et al 1999; Bilder et al 2002; Barkic et al 2003) and
exert a beneficial effect on affective symptoms (Tollefson
et al 1998; Peuskens et al 2000, 2002; Buckley 2004). In
addition, the atypical agents have also been shown to
enhance quality of life, functional status, and patient
satisfaction compared with conventional antipsychotics
(Meltzer 1990; Franz et al 1997; Revicki et al 1999; Colonna
et al 2000; Hamilton et al 2000). This is of particular
relevance since patient satisfaction has been recognized as
an important determinant of treatment success (Kane 2001;
Lambert and Naber 2004). Furthermore, a number of meta-
analyses have demonstrated that, compared with
conventional agents, the use of atypical antipsychotics is
associated with a lower incidence of extrapyramidal side
effects (EPS) (Leucht et al 1999; Geddes et al 2000; Bagnall
et al 2003). However, despite their identified benefits, the
issue of non- and partial compliance with therapy has not
been fully resolved with the newer atypical agents. More
than 35% of patients begin to demonstrate compliance
problems during their first 4–6 weeks of treatment and by 2
years, 75% are partially compliant (Weiden and Zygmunt
1997). Moreover, results from a study by Dolder et al, which
compared compliance rates with oral atypical vs oral
conventional antipsychotics, reported similar, low levels of
compliance in both groups after 12 months (54.9±26.0% vs
50.1±30.6%; p=0.11) (Dolder et al 2002).
It is only recently, with the introduction of long-acting
risperidone launched in North America in 2004, that
clinicians have had access to a long-acting atypical
antipsychotic. Since an earlier study reported that
psychiatrists would be persuaded to use these agents if any
atypical long-acting antipsychotics were available (Patel et
al 2003), the introduction of long-acting risperidone raises
new questions regarding the treatment of patients with
schizophrenia. The aim of this review is to provide an
evaluation of the pharmacokinetics, efficacy, safety and cost-
effectiveness of long-acting risperidone for the treatment
of schizophrenia and schizoaffective disorder.
Methods
A literature search was performed in two parts. Firstly, an
electronic search of English language articles published
between January 2000 and October 2006 that evaluated the
pharmacokinetics, efficacy, safety, and cost-effectiveness
of long-acting risperidone for the treatment of schizophrenia
and schizoaffective disorder was performed using Medline
and EMBASE. The primary search parameters were “long-
acting injectable risperidone”, “schizophrenia”,
“schizoaffective disorder”, “efficacy”, “tolerability”,
“safety”, “quality of life”, “patient satisfaction”,
“pharmacokinetics”, cost-effectiveness”, and
“pharmacoeconomic”. Original research articles, reviews,
and other articles of interest were reviewed. Secondly,
abstracts and posters on long-acting risperidone presented
at key psychiatry and schizophrenia congresses during this
period were also reviewed, where available in the public
domain.
Results
Overview of pharmacokinetic
properties
Technology
Long-acting risperidone is synthesized by a microsphere
encapsulation process using static flow methods to
incorporate risperidone inside a glycolide/lactide matrix, a
commonly used medical polymer. In vitro studies have
demonstrated that a small amount of risperidone at the
surface of the microspheres is released by diffusion within
24 hours. This is followed by a latent period of
approximately 3 weeks, while the majority of the release
occurs by erosion of the glycolic acid-lacate polymer during
weeks 4–6 (Ramstack et al 2003). Following administration,
the copolymer gradually breaks down in the body, steadily
releasing risperidone at a constant rate (Ramstack et al 2003;
Eerdekens et al 2004). The final end products of long-acting
risperidone are risperidone and naturally occurring glycolic
and lactic acids, which are further metabolized to carbonNeuropsychiatric Disease and Treatment 2007:3(1) 15
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dioxide and water (Nordstrom et al 1993). It is theorized
that the sustained release of risperidone from the
microspheres results in consistent and continuous
antipsychotic coverage by reduction of the peaks and troughs
observed with oral medication (Eerdekens et al 2004). The
erosion of the microsphere with subsequent dispersion of
risperidone is illustrated in Figure 1.
Pharmacokinetic profile
The release profile of risperidone microspheres in vitro has
been confirmed in a number of clinical studies. Risperidone
is metabolized principally by the cytochrome P450 2D6
(CYP) enzyme to the active metabolite 9-OH-risperidone
with the sum of the two being frequently modeled for
pharmacokinetic purposes and labelled the “active moiety”.
The results of pharmacokinetic dose trials support the
administration of long-acting risperidone every 2 weeks to
maintain plasma levels of active moiety comparable to levels
obtained with repeated oral dosing.
Single-dose studies have demonstrated that, starting from
about week 3 after the injection, plasma levels of the active
moiety gradually increase, peaking at 4–5 weeks and lasting
approximately 7 weeks (Ereshefsky and Lacombe 1993).
With repeated injections, steady-state levels are usually
reached by 6–8 weeks from the start of therapy, with
significantly reduced peak-trough fluctuations as compared
with oral dosing (Figure 2). Oral risperidone is not required
past the initial stabilization phase. The pharmacokinetic
profile of long-acting risperidone has also been evaluated
in multidose studies. Results from an open-label, non-
randomized, Phase I study in 13 stable outpatients with
schizophrenia who received long-acting risperidone 25, 50,
or 75 mg once every 2 weeks for 5 injections demonstrated
that stable plasma concentrations were reached after the third
injection, maintained for 4–5 weeks and then declined
rapidly with a half-life of 4–6 days (Gefvert et al 2005). An
additional 15-week, open-label study was conducted to
evaluate the pharmacokinetics of multiple doses of long-
acting risperidone in 86 stable patients. Patients stabilized
on 2, 4, or 6 mg/day of oral risperidone once-daily for at
least 4 weeks were assigned to receive 25, 50, or 75 mg of
long-acting risperidone respectively, every 2 weeks for 10
weeks (Eerdekens et al 2004). The 90% confidence intervals
for the long-acting/oral ratios of the mean steady-state
plasma area under the curve to day 14 demonstrated that
they were within the range of 80%–125%, indicating
bioequivalence between the two formulations. However,
mean steady-state peak concentrations of the active moiety
were 25%–32% lower with long-acting risperidone than oral
dosing (p<0.05), and fluctuations in plasma active moiety
levels were substantially lower with long-acting risperidone
(range 56%–71%) compared with oral treatment (118%–
129%). In addition, both a clinical improvement in symptom
Figure 1 The dispersion of risperidone from microspheres. Reproduced with
permission of Wolters Kluwer Health from Ereshefsky L, Mannaert E. 2005.
Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential
benefits of combining an atypical antipsychotic and a new delivery system. Drugs
R D, 6:129–37. Figure 1 from page 131.
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Figure 2 Schematic representation of plasma concentrations following
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severity and a decrease in extrayramidal symptoms (EPS),
as assessed by the Extrapyramidal Symptom Rating Scale
(ESRS) were observed (Eerdekens et al 2004).
Dopamine D2-receptor occupancy
Dopamine D2-receptor occupancy is an important
consideration in determining efficacy and tolerability.
Previous positron emission tomography (PET) studies have
indicated that optimal clinical response occurs when at least
65% of striatal D2 receptors are occupied, while the risk of
EPS increases notably at D2-receptor occupancy levels
above 80% (Kapur et al 1999, 2000). To date, available PET
data have suggested that dosing long-acting risperidone at
25–50 mg every 2 weeks is sufficient in attaining clinical
response with minimal risk of EPS (Farde et al 2002; Gefvert
et al 2005; Remington et al 2006).
One such PET study evaluated D2-receptor occupancy
for long-acting risperidone at doses of 25, 50, or 75 mg
administered every 2 weeks in 9 patients with schizophrenia
or schizoaffective disorder (Remington et al 2006). Patients
were scanned twice during the 2-week injection interval:
within 3 days after injection (post-injection) and within 5
days before the next injection (pre-injection). Mean post-
and pre-injection D2-receptor occupancy levels for the 25,
50, and 75 mg increased in a dose-dependent fashion and
were 71.0% and 54.0%, 74.4%, and 65.4%, and 81.5% and
75.0%, respectively. Although all three doses of long-acting
risperidone demonstrated peak D2-receptor occupancy levels
above the 65% threshold associated with optimal clinical
response, only the 75-mg dose approximated the 80%
threshold linked to increased risk of EPS (Remington et al
2006). A PET study was undertaken by Gefvert et al to
measure D2-receptor occupancy at steady state in 8 patients
treated with doses of 25 (n=3), 50 (n=3), or 75 mg (n=2) of
long-acting risperidone every 2 weeks (Gefvert et al 2005).
Dose-proportional individual D2-receptor occupancy was
25%–48% in the 25-mg group, 59%–83% in the 50-mg
group, and 62%–72% in the 75-mg group. The ranges of
active moiety concentration were 4.4–8.8 ng/mL, 15.0–
31.2 ng/mL, and 22.5–26.3 ng/mL for the three dosages,
respectively. Although the D2-receptor occupancy at the 25-
mg dose seems somewhat lower than what is considered
necessary for an antipsychotic effect, it should be taken into
account that the dopamine D2-receptor occupancies in this
small trial were trough levels and do not exclude higher
occupancies at peak plasma concentrations (Gefvert et al
2005). However, Farde et al estimated individual D2-receptor
occupancy values of long-acting risperidone at both trough
and peak concentrations in a large Phase III clinical trial by
using plasma concentration and receptor binding data from
the study by Gefvert et al (Farde et al 2002). Results
suggested that most patients who responded well to the
25 mg dose had D2-receptor occupancy values of 50–70%
at trough, shifting to values above 70% at peak. Patients in
the 50 mg group had simulated D2-receptor occupancies
covering the target range of 70–80%, while patients
receiving the 75 mg dose had D2-receptor occupancies that
were higher than desirable (57% of patients >80% D2-
receptor occupancy) with no added clinical benefit (Farde
et al 2002).
Clinical efficacy of long-acting
risperidone
Long-acting risperidone is available in dosage strengths of
25, 37.5, or 50 mg. Although not commercially available,
several pivotal studies have also investigated the use of a
75-mg dose. As such, results pertaining to the 75-mg dose
are also discussed here. The short-term (vs placebo) and
long-term clinical benefits of long-acting risperidone were
explored in two large clinical trials, in which long-acting
risperidone was administered by intramuscular injection at
doses of 25, 50, and 75 mg every 2 weeks (Fleischhacker et
al 2003; Kane et al 2003). A more recent study has also
investigated the use of a 37.5-mg dose (Möller et al 2005).
Pivotal and switch studies with long-acting
risperidone
In a 12-week, randomized, placebo-controlled trial by Kane
et al, long-acting risperidone was associated with
significantly greater improvements in Positive and Negative
Syndrome Scale (PANSS) and Clinical Global Impression
(CGI)-severity scores at endpoint compared with placebo
(p<0.001) (Kane et al 2003). Significant improvements in
total PANSS scores (p<0.01), positive symptoms (p<0.01),
and negative symptoms (p<0.001) were also observed during
an international, open-label, 1-year study conducted by
Fleischhacker et al in patients with schizophrenia who were
switched to long-acting risperidone from oral or long-acting
conventional or oral atypical antipsychotics (Fleischhacker
et al 2003). Results from a number of clinical studies and
sub-analyses of the 1-year trial have also reported significant
and sustained clinical improvement in patients switched,
directly or indirectly, to long-acting risperidone from oral
and long-acting antipsychotic agents. Overall, with the
exception of the 4-year open-label extension study byNeuropsychiatric Disease and Treatment 2007:3(1) 17
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Kushner et al, results from the pivotal studies reported
continuation rates with long-acting risperidone (51%–92%)
(Chue et al 2005a; Fleischhacker et al 2003; Kane et al 2003;
Kushner et al 2004; Lindenmayer et al 2004; Turner et al
2004; Emsley et al 2005; Kissling et al 2005; Möller et al
2005). Furthermore, across the pivotal studies, withdrawals
due to insufficient response (range 1.2%–12.2%) and lack
of compliance (range 1.3%–5%) with long-acting
risperidone were low. An overview of pivotal studies and
sub-analyses that have evaluated the efficacy of long-acting
risperidone in patients with schizophrenia and
schizoaffective disorder is summarized in Table 1. It is
recommended that the original studies be reviewed given
the different designs, durations, and objectives of these
studies. For example in the studies by Chue et al (2005a)
and Fleischhacker et al (2003), the dose of long-acting
risperidone was based upon clinical judgement thus, more
severe patients tended to receive the higher dose potentially
accounting for treatment failures at this dose. Furthermore,
since the benefit of a long-acting antipsychotic is accrued
in the longer-term (Gastpar et al 2005; Turner et al 2004;
Lee et al 2006; Lindemayer et al 2006,), this may not be
apparent initially in short-term studies especially when
compared to patients switched from active treatment to
placebo who can show a relative improvement to begin with
that may be associated, for example, with the lack of
medication side effects (Kane et al 2003). Switching
antipsychotics is not without its complexities (Remington
et al 2004) and the unique pharmacokinetics of long-acting
risperidone may influence the outcome in short-term studies
involving switching in stable patients (Lindenmayer et al
2004), or in patients that were previously on high dose or
combination antipsychotic therapies (Kane et al 2003).
Long-acting conventional antipsychotic and long-
acting risperidone studies
Few studies have examined the efficacy of long-acting
risperidone compared with a long-acting conventional agent.
This likely due to the fact that randomization to conventional
depot is no longer considered a standard of treatment for
patients with schizophrenia, and such a study would not be
acceptable to the majority of research ethics boards
(certainly in North America and Canada) (Quraishi and
David 2000). Thus, the two studies that have examined long-
acting injectable treatments have been open-label
comparisons in special populations. In the first 6-month
study, 115 patients fulfilling the criteria for schizophrenia
and substance abuse disorder were allocated to receive either
long-acting risperidone (n=57) or long-acting
zuclopenthixol (n=58). Overall, long-acting risperidone
(mean dose 47.2 mg q15 days and 3.4 mg oral risperidone)
was shown to be more effective than long-acting
zuclopenthixol (mean dose 200 mg q21 days and 15 mg oral
zuclopenthixol) in improving the symptoms of
schizophrenia (mean [±SD] PANSS total scores improved
from 93.79±22.9 at baseline to 64.39±19.9 at endpoint for
the long-acting risperidone group vs 93.69±22.5 at baseline
to 74.03±20.9 for the long-acting zuclopenthixol group).
Long-acting risperidone was also more effective in treating
substance abuse (mean [±SD] number of total positive tests
for substance abuse: long-acting risperidone 8.67±3.0 vs
10.36±3.1 for long-acting zuclopenthixol, p=0.005). More
patients receiving long-acting risperidone attended more
than 75% of addiction counselling sessions compared with
patients receiving long-acting zuclopenthixol (92.9% vs
67.8%, p=0.001) (Rubio et al 2006). In the second study of
chronic hospitalized patients with schizophrenia followed
up for one year, of 40 patients treated with long-acting
risperidone, 83% were discharged and none readmitted. In
contrast, of 54 patients treated with conventional depot, 58%
were discharged and 26% re-admitted (Snaterse et al 2005).
Oral atypical antipsychotics and long-acting
risperidone studies
The large and often contradictory literature examining the
efficacy of oral atypical antipsychotics in head-to-head
comparisons illustrates the difficulty in demonstrating
substantial differences between efficacious agents
particularly when dosing and titration are controlled. A non-
inferiority analysis of oral risperidone and long-acting
risperidone found that long-acting risperidone was as
efficacious and as well tolerated as oral risperidone in a 20-
week randomized, double-blind, double-dummy study
(Chue et al 2005a). It is known from earlier studies with
conventional antipsychotics comparing a long-acting
injection to its oral equivalent, that benefits secondary to
improved compliance are demonstrated with greater
duration of study and maintenance of adequate serum levels
(Jayaram et al 1986). Since non-compliant patients, although
representing a significant proportion of real-world patients
with schizophrenia and other psychoses, are rarely recruited
to clinical trials, this poses problems in demonstrating the
benefit of a treatment that is likely to be advantageous in
that very population. The only other study presented to date
comparing long-acting risperidone injection to an oral
atypical antipsychotic is being conducted in first-episodeNeuropsychiatric Disease and Treatment 2007:3(1) 18
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Efficacy, safety, and cost-effectiveness of long-acting risperidone
patients. Malla et al have shown preliminary data on a 24-
month, prospective, open-label, multi-center study in young
adults (aged 18–30 years) with recent onset
schizophreniform disorder, schizophrenia, and
schizoaffective disorder (≤3 years) (Malla et al 2006). The
effectiveness data set is very small (n=15), but mean changes
in CGI-S (±SD) and total PANSS scores for long-acting
risperidone were –0.7±1.3 and –16.1±16.2 respectively, and
for oral atypical antipsychotics were –0.2± 0.8 and –
5.0±12.9 respectively.
Achieving and maintaining remission in
schizophrenia
Recently, operational criteria for remission in schizophrenia
have been proposed by the Remission in Schizophrenia
Working Group (Andreasen et al 2005). The consensus
definition of remission was defined as achieving a score ≤3
(mild or less) simultaneously in eight core PANSS items:
delusions [P1], conceptual disorganization [P2],
hallucinations [P3], unusual thought content [G9],
mannerisms and posturing [G5], blunted affect [N1],
passive/apathetic social withdrawal [N4], and lack of
spontaneity and flow of conversation [N6], sustained for a
minimum duration of 6 months (Andreasen et al 2005).
To date, the consensus remission criteria have been
retrospectively applied to two clinical studies, which
primarily evaluated the efficacy of long-acting risperidone
(Table 1) (Kissling et al 2005; Lasser et al 2005b). The first
was a sub-analysis of the 1-year trial by Fleischhacker et al
(2003) in patients with schizophrenia who were switched
to long-acting risperidone from oral or long-acting
conventional or oral atypical antipsychotics. Although all
patients in this study were considered clinically “stable” at
baseline, 68.2% (394/578) did not meet the symptom-
severity component of remission at baseline (Lasser et al
2005b). Following treatment with long-acting risperidone,
20.8% (n=82) of non-remitted patients achieved symptom
remission for at least 6 months, with significant decreases
in mean PANSS total and subscale scores (p<0.0001).
Finally, out of the 184 patients who met the symptom-
severity component of the remission criteria at baseline,
84.8% (n=156) maintained their remitted status after 1 year
of treatment (Lasser et al 2005b).
The second study assessed data from an extension phase
of a 6-month trial in 715 stable psychotic patients who were
transitioned directly from their previous antipsychotic
regimen to long-acting risperidone (25, 37.5, or 50 mg),
without an oral risperidone run-in (Kissling et al 2005). The
proportion of patients who met the PANSS severity criteria
for remission increased from 209 (29%) at baseline to 429
(60%) at endpoint. Among those patients who met the
severity criteria at study entry, 84% met them at endpoint.
Furthermore, 79% of those patients met both the severity
and the duration criteria for remission at endpoint. Of the
506 patients who did not meet the severity criteria at
baseline, 50% did so at endpoint. At 12 months 31% of those
patients met both the severity and duration criteria and were
therefore considered to be in remission (Kissling et al 2005).
Health-related quality of life, patient satisfaction
and functioning
The concept of health-related quality of life (HRQoL) has
not been a treatment outcome focused upon in studies until
the last few years. Nonetheless, when patients are asked
directly what is important to them in terms of treatment, it
is in fact such measures as improvement in overall
happiness, mental health and functionality (Hufnagel et al
2004). These patient benefits are not easily shown through
standard studies conducted in the context of drug registration
and approval, which are designed with very specific efficacy
and tolerability perspectives.
Results from the 6-month study by Möller et al (2005)
and a number of its sub-analyses have demonstrated that
patients experience significant improvements in HRQoL and
patient satisfaction following treatment with long-acting
risperidone (Table 1). In addition, a number of studies have
been specifically undertaken to examine the effect of long-
acting risperidone on QoL and social functioning. A post-
hoc analysis by Nasrallah et al measured HRQoL using the
SF-36 scale in patients who participated in the 12-week study
by Kane et al (2003) (Nasrallah et al 2004). At week 12,
patients receiving long-acting risperidone 25 mg and 50 mg
had improved significantly in five of the eight domains of
the SF-36 (bodily pain, general health, social functioning,
role-emotional, and mental health) compared with patients
receiving placebo. No significant differences in seven of
the eight measures were observed between the long-acting
risperidone 25-mg subject group and US normal population
scores (individuals aged 35–44 years). In contrast, subjects
in the placebo group had a significantly poorer QoL
compared with the US normal population in all measures
(p<0.01). Similarly, a sub-analysis of the data from the 1-
year study by Fleischhacker et al also found that long-acting
risperidone resulted in a significant improvement on the SF-
36 Mental Component Summary score and on the vitality
and social functioning scales (Fleischhacker et al 2005).Neuropsychiatric Disease and Treatment 2007:3(1) 26
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Recently a 1-year, randomized, double-blind, multicenter
study was undertaken to examine the effects of long-acting
risperidone on social functioning using the Personal and
Social Performance (PSP) Scale (Rodriguez et al 2005). The
PSP scale provides a clinician rating of personal and social
functioning on a 100-point scale based on the assessment
of patient’s functioning in four important domains: a)
socially useful activities, including work and study; (b)
personal and social relationships; (c) self-care; and (d)
disturbing and aggressive behaviors (Morosini 2000).
Results demonstrated significant improvements in the
Personal and Social Performance Scale (PSP) scores from
baseline to endpoint (p=0.003). In addition, assessments on
the Strauss-Carpenter Level of Functioning Scale (LOF)
indicated that patients had a greater frequency of social
contacts, increased quality of relationships, and a improved
overall level of function during maintenance treatment with
long-acting risperidone.
Safety and tolerability of long-acting
risperidone
On the basis of the results from the studies by Kane et al
and Fleischhacker et al, long-acting risperidone generally
appears to be well tolerated, with an overall incidence of
adverse events similar to that with placebo in comparative
trials. In the study by Kane et al, similar proportions of
patients in the placebo and long-acting groups (80%–83%)
reported adverse events, while serious adverse events were
more frequent in the placebo group (23.5%) than in the 25,
50, and 75 mg long-acting risperidone groups (13%, 14%,
and 15%, respectively) (Kane et al 2003). Likewise long-
acting risperidone was also well tolerated in the long-term
study by Fleischhacker et al with the percentage of patients
reporting adverse events declining from 68% during months
1–3 of the study to 43% during months 10–12 (Fleischhacker
et al 2003). Results from a number of studies have also
reported that patients can be safely transitioned from oral
conventional or atypical therapy and conventional long-
acting agents to long-acting risperidone (Lasser et al 2004a;
Lindenmayer et al 2004; Turner et al 2004; van Os et al
2004). Furthermore, one such study by Möller et al
demonstrated that switching from existing antipsychotic
therapy to long-acting risperidone, without an oral
risperidone run-in, was well tolerated in a large cohort of
patients with schizophrenia or other psychotic disorders
(Möller et al 2005). Several studies have also reported that
patients considered symptomatically stable on oral
risperidone can be safely switched to long-acting risperidone
(Chue et al 2005a; Lasser et al 2005a), thereby contradicting
the perception of some clinicians and patients that adverse
events are more common with long-acting than with oral
formulations.
Overall, relatively few patients have withdrawn in
studies with long-acting risperidone due to adverse events
(range 1.2%–16%) (Fleischhacker et al 2003; Kane et al
2003; Kushner et al 2004; Lindenmayer et al 2004; Turner
et al 2004; Chue et al 2005a; Lasser et al 2005a; Möller et
al 2005; Emsley 2006). The most common adverse events
reported with long-acting risperidone were headache (range
7%–28%), insomnia (range 7%–28%), anxiety (range 7%–
24%), and psychosis (range 5%–31%). In the majority of
studies the severity of movement disorders, as assessed by
the ESRS, was unchanged or further reduced during
treatment with long-acting risperidone. In addition, a sub-
analysis of the 1-year study demonstrated that long-acting
risperidone is associated with a low incidence of treatment-
emergent dyskinesia (1.2% annually) (Gharabawi et al
2005). Three studies, which examined the effect of long-
acting risperidone on serum prolactin levels, reported rates
of hyperprolactinemia of 1.3%–7% (Lindenmayer et al
2004; Turner et al 2004; Chue et al 2005a).
Metabolic side-effects in patients treated with atypical
antipsychotic agents are increasingly receiving more
attention in the literature, with recent evidence suggesting
that some atypical antipsychotics may increase risk factors
for diabetes and cardiovascular disease, including increased
adiposity and adverse effects on glucose and lipid
metabolism (ADA 2004; Citrome 2004). On the basis of
the limited evidence presented here from the pivotal trials,
weight gain with long-acting risperidone was low, being in
the range of 0.5–2 kg in the short-term (12 weeks) and
around 3 kg after 1 year of treatment, with no further weight
gain apparent in patients receiving long-acting risperidone
for up to 4 years (Kushner et al 2004). In addition, results
from a short-term study demonstrated that serum glucose
and triglyceride levels were reducing during treatment with
long-acting risperidone (Lindenmayer et al 2004), while a
further study reported a low occurrence (0.3%) of glucose-
related adverse events over 6 months (Möller et al 2005).
Finally, in the patient populations studied, including
antipsychotic injection-naive patients, the perception of pain
at the injection site was rated as mild and decreased over
time (Fleischhacker et al 2003; Kane et al 2003;
Lindenmayer et al 2004; Turner et al 2004; Chue et al 2005a;
Lindenmayer et al 2005). It is postulated that the low
incidence of injection site pain could be related to the factNeuropsychiatric Disease and Treatment 2007:3(1) 27
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that long-acting risperidone is an isotonic water-based
suspension has been shown to be easier and less painful to
administer than the oil-based solutions of the conventional
long-acting antipsychotic agents (Bloch et al 2001). A full
overview of the safety data for long-acting risperidone is
also shown in Table 1.
Efficacy and safety of long-acting
risperidone in special populations
Certain populations such as the elderly, young adults or those
with a first episode of schizophrenia, patients with
schizoaffective disorder and patients of different ethnicity
require special consideration when selecting
pharmacotherapy. A number of studies have demonstrated
that long-acting risperidone is both effective and well
tolerated in these populations (Table 2). However, it is
important to note that these results are based solely on sub-
analyses and interim analyses and, as such, further controlled
studies of long-acting risperidone in these vulnerable patient
groups are warranted.
Elderly patients
Elderly patients with schizophrenia have generally been
neglected in the research literature, but often suffer from
persistent symptoms and cognitive deficits (Davidson et al
2000). Elderly patients also have a greater sensitivity to
treatment-related adverse effects, a higher rate of co-
morbidities and an increased risk of medication interactions
(Masand 2000). A sub-analysis of the 12-month study by
Fleischhacker et al examined the efficacy and safety of long-
acting risperidone in elderly patients (≥65 years) with
schizophrenia and schizoaffective disorder (Lasser et al
2004c). Long-acting risperidone was associated with
significant improvements as determined by PANSS
(p<0.001) and CGI-S assessment scales. Moreover, despite
the age of this population and high rate of polypharmacy,
the incidence of adverse events of particular concern such
as cardiac effects and movement disorders, was low.
Importantly, no new cases of tardive dyskinesia were
reported in this high-risk group and symptoms of movement
disorders were reduced compared to baseline (Lasser et al
2004c).
Young patients or patients with a first episode of
schizophrenia
The early recognition and management of first-episode
schizophrenia is a challenging task. Although these patients
are the most responsive to treatment, they are also very
sensitive to adverse events and often lack “disease insight”,
which contribute to poor compliance and high treatment
discontinuation rates (Kasper 1999). A recent subanalysis
of the 6-month study by Möller et al examined the efficacy
and safety of long-acting risperidone in patients in the early
phases of schizophrenia and schizoaffective disorders
(Parellada et al 2005). Following initiation of long-acting
risperidone statistically significant improvements were seen
in the control of symptoms and the severity of schizophrenia
(both PANSS and CGI-S), as well as Global Assessment of
Functioning (GAF), HRQoL, patient satisfaction, and EPS
(Parellada et al 2005). A number of other sub-analyses have
also reported that long-acting risperidone was efficacious
and well accepted in young adults with schizophrenia or
schizoaffective disorder (Lasser et al 2004d; Saleem et al
2004) (Table 2). In addition, Emsley et al, has reported on
the 6-month interim data on 51 patients with first episode
psychosis with 74% of patients achieving ≥50% reduction
in the PANSS (Emsley et al 2005).
Patients with schizoaffective disorder
Schizoaffective disorder is a complex disorder to both
diagnose and successfully treat, often requiring a
combination of different classes of medications including
an antipsychotic and an antidepressant or mood stabiliser
(Levinson et al 1999). Two analyses were identified which
examined the efficacy of long-acting risperidone in stable
patients with schizoaffective disorder (Lasser et al 2004b;
Mohl et al 2005) (Table 2). Data from these two studies
suggest that significant clinical benefits follow a switch to
long-acting risperidone in symptomatically stable patients
with schizoaffective disorder, despite the fact that PANSS
scores were low at baseline and further clinical improvement
would not necessarily be anticipated. Of particular note for
patients with schizoaffective disorder were the significant
improvements in the two symptom domains relating to mood
– the anxiety/depression factor and the uncontrolled
hostility/excitement factor (Lasser et al 2004b; Mohl et al
2005). The reduction in psychopathology symptoms was
also accompanied by significant improvements in CGI-S
scores, GAF scores and improvements in HRQoL, as
assessed by the SF-36 (Lasser et al 2004b; Mohl et al 2005).
Patients of different ethnicity
Several studies have suggested that African-American
patients may respond differently to treatment than do other
racial or ethnic groups (Emsley et al 2002). The nature of
these differences is poorly understood but may reflectNeuropsychiatric Disease and Treatment 2007:3(1) 28
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genetic, pharmacokinetic, cultural, or environmental factors
(Frackiewicz et al 1997; Poolsup et al 2000). To date, the
impact of race on the efficacy and safety of long-acting
risperidone in Caucasian, African-American and other
patients with schizophrenia or schizoaffective disorder has
been examined in a sub-analysis of the 12-week, placebo-
controlled study by Kane et al (Ciliberto et al 2005) (Table
2). Results demonstrated that there was a significant effect
of treatment (p<0.001), independent of race, on the
improvement in mean PANSS total scores.
Obese patients
Weight gain and obesity have been reported in patients
receiving both conventional and atypical antipsychotics, and
are associated with increased risks for hypertension, stroke,
osteoarthritis, and particularly for coronary heart disease
and type 2 diabetes (Gang uli 1999). To date, one study has
been undertaken to investigate the efficacy of long-acting
risperidone in obese patients (body mass index of ≥30 kg/
m
2) with schizophrenia or schizoaffective disorder (Table
2). Results demonstrated that there were significant
reductions from baseline in mean total PANSS scores at 1
month and these continued throughout the trial. Overall,
the efficacy of long-acting risperidone in obese patients was
comparable to that reported for schizophrenia patients in
general (Marder et al 1997). Importantly, bodyweight
remained stable throughout the 6-month study period, with
a mean increase of 0.5 kg. Furthermore, despite the high
BMI of the patients, approximately half of the patients
remained on the starting dose of long-acting risperidone
throughout the study.
The cost-effectiveness of long-acting
risperidone
Healthcare costs in schizophrenia are disproportionately
high. Although the illness affects approximately 1% of the
world’s population, it accounts for up to 3% of health
expenditure (Knapp 2000). Relapses increase refractoriness
to future treatment leading to more frequent and prolonged
hospitalization, and contribute significantly to the economic
burden of schizophrenia. Results from a recent study
demonstrated a four-fold increase in costs among patients
experiencing relapse, compared to those who did not
(Almond et al 2004). Overall, 79% of the direct costs of
schizophrenia result from hospitalization or other residential
care, while medications represent only a small fraction (1%–
6%) of the total cost of schizophrenia (Foster and Goa 1998;
Davies and Drummond 1994; Goeree et al 2005). It is
expected that the introduction of long-acting risperidone
with its potential to improve compliance and decrease relapse
should lead to lower levels of healthcare resource use.
Hospitalization rates, healthcare resource
utilization, and relapse rates with long-acting
risperidone
Hospitalization rates were assessed as part of a 1-year
international, open-label trial of long-acting risperidone in
inpatients and outpatients with stable schizophrenia or
schizoaffective disorder (Chue et al 2005b). Of the 397
patients who received a modal dose of long-acting
risperidone 25 mg or 50 mg, 24% were inpatients and 76%
were outpatients at baseline. Results demonstrated that the
number of patients requiring hospitalization decreased
continuously and significantly from 38% in the 3 months
before treatment to 12% during the last 3 months of treatment
(p<0.001). Of baseline inpatients, 71% were discharged
during treatment. Overall, the 1-year re-hospitalization rate
was 17.6%, with a rate of 15.9% for baseline outpatients
(Chue et al 2005b). A further analysis of this study examined
healthcare resource utilization during 1-year treatment with
long-acting risperidone (Leal et al 2004). Results
demonstrated that mean hospitalization length during the
study was 30.5 days (outpatients, 4.9 days; inpatients 110
days). The need for partial hospitalization (day or night
clinics) decreased significantly over the 12-month period,
from 7% during the 12 weeks before treatment to 3% during
the last 12 weeks (p=0.002). The need for outpatient
consultations also decreased significantly from 70% in the
12 weeks before treatment to 30% (p<0.0001) during the
first 12 weeks of treatment. The need for outpatient
consultation remained stable throughout the remainder of
the treatment period. Overall, only 9% of patients required
an emergency room visit, mostly for non-psychiatric
conditions (Leal et al 2004).
Results from a multicenter, Canadian retrospective study
reported that following a switch to long-acting risperidone
92% fewer patients (4.3%) were hospitalized post-initiation
compared with prior (50.7%), (p<0.0001). Furthermore,
total duration of hospitalization days decreased by 99%
(p<0.0001) and anticholinergic and anxiolytic use fell by
22% (p=0.0719) and 38% (p=0.0252), respectively (Chue
et al 2005d). Of note, preliminary data from a Swedish
multicenter study in 92 patients have demonstrated that for
patients treated with long-acting risperidone, the total
number of hospitalizations was reduced by 38% (p=0.0004)
compared with the same observational period when treatedNeuropsychiatric Disease and Treatment 2007:3(1) 33
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with their previous antipsychotic therapy (Eriksson et al
2003). Using an empirical economic model, based on the
Swedish costs, the mean annual cost savings can be
calculated per patient following a switch to long-acting
risperidone within the recommended dose range (Figure 3).
Finally, a 1-year mirror image observational study was
undertaken to investigate predictors of relapse (defined as
hospital admission) for patients (n=142) on long-acting
risperidone (Patel et al 2006). Results demonstrated that
patients who discontinued long-acting risperidone (0–12
months) were 3 times more likely to relapse than continuers
at 1 year (odds ratio [OR] 3.08, 95% confidence interval
[CI]: 1.39–6.81, p=0.003). Clinically unstable patients (those
admitted in the year preceding long-acting risperidone
treatment) were much more likely to relapse than those who
were clinically stable (OR 6.58, 95% CI: 2.77–15.66,
p<0.001). No statistically significant differences were found
for relapse in terms of sociodemographic factors, diagnosis
and illness duration, medication history and clinical
indication for long-acting risperidone (Patel et al 2006). As
such, patients who receive consistent and continuous
treatment with long-acting risperidone may be expected to
have a lower incidence of relapse rates and, therefore, an
improved long-term prognosis.
Pharmacoeconomic evaluations of long-acting
risperidone
The use of modeling as a means of assessing the economics
of health interventions has increased considerably in recent
years. A number of studies have employed either discrete
event simulation or decision analytic models, both of which
theoretically address the heterogeneous and real-world
characteristics of patients with schizophrenia, to examine
the costs of long-acting risperidone compared with oral and
conventional long-acting agents in the US, Canada,
Belgium, and Germany (Chue et al 2005c; De Graeve et al
2005; Edwards et al 2005; Laux et al 2005).
In the US, a decision analytical model captured rates of
patient compliance, rates, frequency and duration of relapse,
incidence of adverse events, and healthcare resource
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utilization and associated costs with 7 treatment alternatives
(Edwards et al 2005). Primary outcomes were expressed in
terms of percentage of patients relapsing per year, number
of relapse days per year, and total direct 2003 medical cost
per patient per year. On the basis of model projections,
patients receiving long-acting risperidone will have the best
clinical outcomes in terms of the frequency and duration of
relapses. Over a period of 1 year, this would translate into
direct medical cost-savings with long-acting risperidone
compared with oral risperidone, olanzapine, quetiapine,
ziprasidone, aripiprazole, and long-acting haloperidol of
US$161, 1425, 508, 259, 1068, and 8224, respectively
(Edwards et al 2005).
In Canada, a discrete-event model was designed to
evaluate the cost-effectiveness of long-acting risperidone
for patients with schizophrenia at a high risk of non-
compliance, compared with 2 standard treatment alternatives
(oral risperidone and long-acting haloperidol) over a 5-year
period (Chue et al 2005c). On the basis of 3000 simulated
patient characteristics, the model generated individual
patient histories. Outcomes included the number and
duration of psychotic episodes, the cumulative PANSS score
and direct medical costs. The time horizon of the model
was 5 years and a 5% discount rate was used for costs and
effects. In this model, initiating treatment with long-acting
risperidone was the dominant strategy. After 5 years,
treatment with long-acting risperidone saved Can$6908 and
Can$13130 (discounted) and avoided 0.28 and 0.54 relapses
per patient, compared with long-acting haloperidol and oral
risperidone, respectively (Chue et al 2005c).
In the Belgian model, a decision tree model was created
to compare the cost effectiveness of three first-line treatment
strategies in a sample of young schizophrenia patients who
had been treated for 1 year and whose disease had not been
diagnosed for longer than 5 years (De Graeve et al 2005).
This model used a time horizon of 2 years, with health state
transition probabilities, resource use and cost estimates
derived from clinical trials, expert opinion, and published
prices. The principal efficacy measure was the proportion
of patients successfully treated, defined as those who
responded to initial treatment and who had none to two
episodes of clinical deterioration without needing a change
of treatment over the 2-year period. A greater proportion of
patients were successfully treated with long-acting
risperidone (82.7%) for 2 years, compared with those treated
with oral olanzapine (74.8%) or long-acting haloperidol
(57.3%). Total mean costs per patient over 2 years were
•16 406 with long-acting risperidone, •17 074 with
olanzapine, and •21 779 with long-acting haloperidol (year
of costing 2003) (De Graeve et al 2005). Similarly, the mean
cost-effectiveness ratios were •19 839, •22 826, and
•38 008 per successfully treated patient for long-acting
risperidone, olanzapine, and haloperidol, respectively. Cost
savings were also observed when long-acting risperidone
was compared with oral olanzapine and long-acting
haloperidol in a German study (Laux et al 2005). In this
study a discrete-event simulation model was developed to
compare the benefits and costs of three pharmacological
treatment strategies from the perspective of major third party
payers (sickness funds and social security) over a 5-year
period in Germany. The model accounted for fixed patient
characteristics, and on the basis of these, simulated patient
histories according to several time-dependent variables. In
accordance with German guidelines, costs and effects were
discounted by between 3% and 10%. Outcomes were
expressed in terms of the number and duration of psychotic
episodes, cumulative symptom scores, costs, and quality-
adjusted-life-years (QALY). The long-acting risperidone
strategy was calculated to avoid 0.23 and 0.33 relapses per
patient, decrease the cumulative symptom score by 25 and
33 points, and decrease costs by •2017 and •6096 per patient
(•1608 and •5422 discounted), compared with the long-
acting haloperidol and olanzapine strategies respectively,
over 5 years (Laux et al 2005).
Discussion
It is recognized that long-acting antipsychotics facilitate
compliance with medication, and may help to prevent relapse
and improve functional outcomes in patients with
schizophrenia (Gerlach 1994). Accordingly, the guidelines
for long-acting antipsychotic treatment that were developed
by a European Neuropsychopharmacology Consensus
Conference recommend that: “any patient for whom long-
term antipsychotic treatment is indicated should be
considered for depot drugs” (Kane et al 1998). The
development of long-acting risperidone, which combines
the benefits of an atypical agent with the advantages of a
long-acting formulation, represents an important new option
for the long-term management of patients with
schizophrenia.
Results from the studies presented here have
demonstrated that long-acting risperidone 35, 37.5, or
50 mg, administered once every 2 weeks, is both effective
and well tolerated in patients with schizophrenia or
schizoaffective disorder (Fleischhacker et al 2003; Kane et
al 2003; Lindenmayer et al 2004; Turner et al 2004; ChueNeuropsychiatric Disease and Treatment 2007:3(1) 35
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et al 2005a; Möller et al 2005). In addition, several patient
groups, including the young, the elderly, patients with
schizoaffective disorder, and patients of different ethnicity
have also been shown to derive significant benefit from long-
acting risperidone. None of these trials, as with studies of
conventional long-acting antipsychotics (Adams et al 2001),
specifically recruited non-compliant patients due to the
difficulties in maintaining such patients in a study thus, the
positive outcomes reported are potentially subject to some
bias. Nonetheless, the favorable efficacy and tolerability
profile of long-acting risperidone is also associated with
improvements in quality of life and patient satisfaction,
thereby helping to reduce the burden on family members
and caregivers and promote social integration (Nasrallah et
al 2004; Fleischhacker et al 2005). Recently, The Remission
in Schizophrenia Working Group defined remission as “a
state in which patients have experienced an improvement
in core signs and symptoms to the extent that any remaining
symptomatology is of such low intensity that it no longer
interferes significantly with behavior, and is below the
threshold typically utilized in justifying an initial diagnosis
of schizophrenia” (Andreasen et al 2005). Although these
newly proposed remission criteria require further
refinement, results from two retrospective analyses have
demonstrated long-acting risperidone may help patients
achieve and maintain remission (Kissling et al 2005; Lasser
et al 2005b). Prospective studies utilizing the consensus
remission criteria as a primary outcome are now eagerly
awaited.
Non- and partial compliance with antipsychotic therapy
remains widespread (Weiden and Zygmunt 1997). The
combination of symptomatic improvement and better
tolerability with long-acting risperidone is expected to
improve compliance with therapy. This is of particular
relevance to young patients or patients with a first episode
of schizophrenia, who are particularly sensitive to adverse
events and are lacking in disease insight, leading to poor
compliance and treatment discontinuation. Indeed, a study
of first-episode patients with schizophrenia demonstrated
that partial compliance increased by nearly five-fold the risk
of both first and second relapse (Robinson et al 1999).
Evidence that long-acting risperidone improves compliance
comes from the finding that across the pivotal studies only
1.3%–5% of patients discontinued treatment with long-
acting risperidone because of poor compliance. Overall, the
high retention rates in these studies (51%–92%) probably
reflects a number of factors: the low incidence of adverse
events (only 1.2%–16% of patients discontinued as a results
of adverse events), the improvement in symptoms, HRQoL,
and patient functioning experienced by patients with long-
acting risperidone treatment, and the fact that long-acting
risperidone was well accepted by patients, supported by the
low rating of subjective pain and absence of objective
changes at the injection site (Lindenmayer et al 2005). This
is in contrast to the overall 74% all-cause discontinuation
rate recently reported from the Clinical Antipsychotic Trial
of Intervention Effectiveness (CATIE) (Lieberman et al
2005). Although some clinicians believe that long-acting
agents are old fashioned, stigmatizing, and less acceptable
to patients (Patel et al 2003), results from a systematic review
of patient preference reported that in 5 out of the 6 studies
analyzed, the majority of patients preferred to receive their
medication via a long-acting formulation than in tablet form
(Walburn et al 2001).
Interestingly, in a number of studies with long-acting
risperidone it has been noted that there has been a reduction
in concomitant medications including side effect
medications (anticholinergics, anxiolytics, hypnotics,
sedatives), antipsychotics used in combination, and other
classes of psychotropics such as antidepressants and mood
stabilizers (Fleischhacker et al 2003; Taylor et al 2004; Chue
et al 2005d; E-STAR 2005; Snaterse 2005). This may be
regarded as a proxy measure of both efficacy and tolerability
in real-world patients and warrants further study.
Medications that can reduce relapse rates and improve
compliance leading to lower levels of healthcare resource
use, particularly hospitalization, are an important part of
the management of schizophrenia. A number of
pharmacoeconomic models and early clinical data have
consistently demonstrated that long-acting risperidone
reduces the number of relapses, compared with oral atypical
or conventional long-acting agents (Eriksson et al 2003;
Chue et al 2005c; De Graeve et al 2005; Edwards et al 2005;
Laux et al 2005). Applying country-specific economic data,
this improvement in the number of relapses has consistently
translated into various levels of cost savings despite very
different healthcare systems (Chue et al 2005c; De Graeve
et al 2005; Edwards et al 2005; Laux et al 2005). These
findings suggest that long-acting risperidone is potentially
a cost-effective first-line strategy for managing
schizophrenia and reducing the burden related to the disease
(Annemans 2005). However, it is recognized that for long-
acting risperidone the results drawn from
pharmacoeconomic model data are limited and must be
supported by real-world observational findings before
definitive conclusions can be made, particularly when theNeuropsychiatric Disease and Treatment 2007:3(1) 36
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cost-effectiveness of conventional long-acting
antipsychotics for schizophrenia has not been consistently
demonstrated (Knapp et al 2002; Kilian and Angemeyer,
2004). Furthermore, an analysis of 22 pharmacoeconomic
evaluations of different drug therapies showed that non-
compliance always resulted in a reduction in efficacy, but
the impact on costs varied substantially (Hughes et al 2001).
It is acknowledged that this review has several
limitations. Firstly, this review includes initial data published
at international congresses that are not yet subject to peer
review, but nonetheless provide clinicians with early and
important information. In addition, since this review
analyzed a large number of clinical trials, encompassing a
wide range of study designs from randomized, control to
open-label, switch studies, variable patients numbers, and
duration of follow-up, it is difficult to make direct
comparisons across studies. The results of the efficacy of
long-acting risperidone in special populations (young
patients, elderly patients, patients with schizoaffective
disorder, and patients of different ethnicity) were based
solely on sub-analyses. As such, further controlled studies
of long-acting risperidone in these difficult-to-treat
populations are warranted. Likewise, the hypothesis that
switching patients from oral or long-acting conventional or
oral atypical antipsychotics may result in significant
improvements also requires further investigation because
the majority of these results were also based on sub-analyses.
Finally, no head-to-head studies with other atypical
antipsychotic agents have been published to date. However,
it remains important to consider all levels of clinical
evidence when evaluating the overall effectiveness of
medication since randomized clinical trials in select study
populations for registration purposes may not always reflect
current and relevant clinical practice objectives.
The unique pharmacokinetics of long-acting risperidone
does have implications when initiating and titrating therapy,
particularly when compared to conventional long-acting
antipsychotics. However, clinical recommendations
concerning dosing are beyond the scope of this review, but
are discussed in a number of clinical articles and in the
Product Monograph (Marder et al 2003; Keith et al 2004;
Viner et al 2006).
Conclusion
This review indicates that long-acting risperidone is suitable
for a wide range of patients, including those who are deemed
clinically stable, to further improve symptom control and
enhance tolerability. The combination of improved efficacy
and good tolerability may have important implications for
patient  compliance  to  therapy  and  subsequent  positive
long-term outcomes including the achievement of
remission.
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